Vera Q3 2026: first Trutakna sales of $10.3M, about half inventory; a rival's FDA date nears
Did the story change? Mixed
Partly, with good and bad news. In its first sales quarter, Vera booked $10.3 million of Trutakna, against the $3.9 million estimate TradingView published, but management says about half of that was inventory. It has about 700 patient start forms and filed for full approval, expected in mid-2027. It used about $99 million of operating cash in the quarter, and Vertex's rival drug has an FDA date of Nov 30. The shares closed down 1.2% at $29.79 on Nov 6.
What it means
- What changed
- Vera is now a selling company: $10.3 million of Trutakna in its first quarter, about half of it inventory, and its full-approval filing is in.
- What hasn't changed
- Trutakna's approval is still accelerated, and Vera still depends on one product and on money it raises or borrows.
- Next · Nov 30, 2026
- FDA target date for Vertex's povetacicept, which also blocks BAFF and APRIL, in the same kidney disease.
Closing prices: $29.79 on Nov 6, 2026 (Yahoo Finance, CNBC) and $30.14 on Nov 5 (Nasdaq, Yahoo Finance, CNBC). The results came after the Nov 5 close.
Snapshot at the Nov 6, 2026 close
- Market value
- $2.2B
- Enterprise value
- $1.8B
- Price/sales
- 209.6×
- EV/sales
- 179.5×
- P/E
- n/m
- Price/FCF
- n/m
- Revenue growth
- n/m
- FCF margin
- −3666%
- Net cash
- $309M
Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $29.79 (official close, Yahoo Finance, CNBC); 72.3 million shares (common shares on the cover page of the 10-Q filed Nov 5, 2026). n/m = not meaningful (e.g. negative earnings).
Vera booked $10.3 million in its first quarter of product sales, against no product revenue a year earlier and its August expectation of “limited revenue”, and the filing for full approval is in. Management says about half of those sales were inventory. The harder part comes next: turning start forms into paying patients as a third drug of this type may reach the market within weeks.
How the stock reacted
Vera closed at $29.79 on Nov 6 (Yahoo Finance, CNBC), down 1.2% in the first session after the results, after trading between $28.04 and $30.84 (CNBC). The S&P 500 rose 0.3%, the Nasdaq Composite 1.1% and a biotech fund, XBI, 2.6% that day (Yahoo Finance, our calculation). The results came after the Nov 5 close, when Vera had already fallen 5.7% to $30.14 in a broad selloff: the S&P 500 fell 4.4% and the Nasdaq Composite 5.5%, AP reported, and XBI fell 6.7% (our calculation).
Vera’s price/sales and EV/sales in the snapshot look very high, about 210 and 180 times, because they rest on one partial quarter of sales since launch, not a full year.
Did the story change?
In August Vera expected “limited revenue” in Q3; it booked $10.3 million. The table compares Q2 figures and earlier updates with the latest results and updates.
| Driver | Earlier → latest | Management: before → now | Signal |
|---|---|---|---|
| Net product sales | None → $10.3M | “Limited revenue” expected in Q3 → launch “building early momentum”; about half of sales were inventory | Better |
| Patient start forms | More than 350 in the first ten weeks → about 700 to date | Forms reported each update; patients on therapy not given | Better |
| Full approval | Filing planned for Q4 → filed Nov 3 | Potential approval “2027” → “mid-2027” | Better |
| Cash and loan | $499.2M → $384.0M; $459M counting a $75M loan draw in October (Vera’s figure) | $75M approval tranche drawn in October; a separate $50M tranche drawable through year-end; up to $350M remains available, subject to conditions | Unchanged |
| Competition | Otsuka’s Voyxact on the market; Vertex’s FDA date Nov 30 | Same date; Vera does not address it in its release or prepared remarks | Watch |
Sources: Q2 and Q3 releases, 10-Qs and call; BioSpace for Vertex’s FDA date. Patient start forms are as Vera reports them, including its September update.
What got better
Sales were above the one published forecast we found, TradingView’s $3.9 million. Vera had about 700 start forms within about four months of approval, and says they come from a broad group of doctors, not a small one. Raymond James analysts (Strong Buy) read an October Spherix Global Insights survey of 75 kidney specialists as showing Trutakna matching Voyxact’s launch pace, Investing.com reported; we have not seen the survey.
The evidence is also firmer. Vera reported that kidney function fell by 0.6 units a year on Trutakna, against 5.6 on placebo, over two years in its ORIGIN 3 trial, and that the risk of disease progression was 76% lower. That is Vera’s account of the trial, which was published in The New England Journal of Medicine. It is the basis of the filing for full approval.
What needs watching
Sales quality is the first test. On the call, Vera’s commercial chief said about half of the $10.3 million was demand and about half inventory, and that he expects the demand share to be much higher in coming quarters. Two customers accounted for 94% of gross product revenue.
Start forms are not patients. Vera does not say how many have started. It says it is on track for a goal of 50% of covered lives by year-end, without saying where coverage stands now. From here it will report forms as of quarter-end and expects revenue to become the main measure of progress.
Spending is rising with the launch. Selling and administrative costs reached $61.4 million, against $52.4 million in Q2, and operating cash use was about $99 million (our calculation)1. Research spending fell to $41.3 million from $60.1 million, partly because manufacturing costs now go into inventory instead. Early sales also use drug made before approval and already expensed, so Vera warns that cost of sales and margins in the first periods may not be indicative.
Competition is the near-term test. Otsuka’s Voyxact is already on sale, and Vertex’s povetacicept, which works the same way as Trutakna, has an FDA date of Nov 30.
Vera reports no material legal proceedings. Its 10-Q also discloses, though the release does not, that it cancelled some research manufacturing in October, which it expects to produce a loss of up to $14.6 million in Q4. It has $88.1 million of minimum manufacturing purchases due through 2027.
If the FDA approves Vertex’s povetacicept by its Nov 30 date
This is a scenario, not a forecast: the FDA has not ruled, and it could approve, delay or reject Vertex’s drug.
If approved, povetacicept would be the second drug to block the same two targets as Trutakna, BAFF and APRIL, and it is given about once a month instead of weekly. Otsuka’s Voyxact, which blocks APRIL only, is also injected every four weeks. Trutakna and Voyxact have two-year kidney-function results; povetacicept’s are still to come. No trial has compared the drugs head to head, so their results don’t line up directly.
The bigger difference may be the seller. Vertex earns more than $10 billion a year from cystic fibrosis drugs, and Chief Commercial Officer Duncan McKechnie says the kidney sales team is “fully hired, trained and ready to go”, BioPharma Dive reported. BMO analysts expect Vertex to benefit from rivals’ work educating doctors. When Trutakna was approved, Jefferies analyst Farzin Haque wrote that “it will come down to commercial execution between the sponsors.” The case for room for several drugs: Voyxact’s head start did not stop Vera collecting about 700 start forms, and a Spherix survey found early Voyxact use concentrated in higher-risk patients rather than replacing other treatments outright.
For Vera, the risks are slower growth in start forms if doctors try a monthly option, harder coverage talks if insurers can choose among three drugs, and pressure on its list price of $425,000 a year, above Voyxact’s $390,000. We found no price for povetacicept. Vera says insurers’ existing step requirements apply to the drug class alike. Its own monthly dose is still in testing, with first results due for internal review this quarter.
If the decision slips, Vera competes with one drug of this type instead of two for longer, with more time to build coverage. Vertex said it is “100% ready” to launch.
How the three drugs compare, signposts, and our arithmetic
| Trutakna (Vera) | Voyxact (Otsuka) | Povetacicept (Vertex) | |
|---|---|---|---|
| Blocks | BAFF and APRIL | APRIL | BAFF and APRIL |
| How given | Self-injected weekly, autoinjector | Self-injected every four weeks, prefilled syringe | Every four weeks; Vertex plans an at-home autoinjector |
| Protein in urine, main trial | 42% lower than placebo at 36 weeks (interim); 46% lower than baseline | 51% lower than placebo at nine months (interim) | 49.8% lower than placebo at 36 weeks (interim) |
| Kidney filtration rate (eGFR), annual change over two years, mL/min/1.73 m² | −0.6, against −5.6 on placebo | +0.3, against −4.2 on placebo | Final analysis at two years; not reported yet |
| US status | Accelerated approval Jul 7, 2026; full-approval filing Nov 3 | Accelerated approval Nov 25, 2025; filing for full approval under way | FDA target date Nov 30, 2026, for accelerated approval |
| List price | $425,000 a year | $390,000 a year | Not announced |
Trutakna’s and Voyxact’s US labels both cover adults with primary IgAN at risk for disease progression. Figures are each company’s, as reported by it or by BioPharma Dive and BioSpace; Trutakna’s 42% and 46% are from Vera’s June 2025 release. The trials differ in design and patients.
Outside views: William Blair analyst Myles Minter called Trutakna’s label “generally competitive” with Voyxact’s but said Otsuka has “distinct first-to-market advantages”, BioPharma Dive reported in July. Stifel analyst Paul Matteis wrote in March that povetacicept’s results left unclear whether it is “differentiated from other key competitors”, the same outlet reported. BMO Capital Markets analysts pointed to Vertex’s “international footprint” and “history of commercial execution”, BioSpace reported. Spherix found that 21% of surveyed nephrologists had prescribed Voyxact within two months of approval, and that coverage and prior authorization shaped when they started it.
Signposts in Q4 and Q1: the FDA decision and povetacicept’s label, including whether it calls for antibody monitoring, which a citizen petition asked the FDA to require, BioPharma Dive reported (Vera says Trutakna needs none); Vertex’s price; Vera’s Q4 start forms, now counted to quarter-end, and how much of its sales are demand rather than inventory; progress toward its goal of 50% of covered lives by year-end; and its monthly-dose results.
Our arithmetic, not a forecast: at the list price, every 1,000 patients treated for a full year would be about $425 million of sales before discounts and rebates. Vera has not said how many patients are on treatment.
Does this change the long-term story?
Our read: it moves Vera from a promise to a launch, without yet showing how large the launch will be. One quarter of sales, about half of it inventory, and a count of forms say little about who stays on treatment. Vera reported $459 million of pro forma September-end cash and securities, adding only the October borrowing and not later spending. With about $99 million of quarterly operating cash use, funding remains worth watching, although management says its resources cover planned operations for at least 12 months after the filing. The next few quarters’ revenue will matter more than this one.
For the full record of filings, dilution and cash, see Vera Therapeutics: The Long View.
Footnotes
-
Q3 = nine months − six months: −$305.929M − (−$206.753M) = −$99.176M. ↩
What to watch next
- Nov 30, 2026
- FDA target action date for Vertex's povetacicept in IgA nephropathy.
- Dec 31, 2026
- Last date to draw a further $50 million of the Oxford loan.
- Q1 2027
- Planned European filing for standard marketing authorisation.
- Mid-2027
- Potential full approval of Trutakna, subject to FDA review of the filing made on Nov 3.
Quick questions
How many patients are on Trutakna?
Vera has not said. It reports about 700 patient start forms received to date, which are requests to begin treatment, not patients on therapy.
What does full approval change?
Trutakna now has accelerated approval, based on reduced protein in the urine. Vera's filing relies on two-year kidney-function data from its ORIGIN 3 trial. It expects a potential full approval in mid-2027, subject to FDA review.
About Vera: Website (external site)Investor relations (external site)SEC filings (external site)
+ 14 more
Accessed Nov 5, 2026: TradingView: VERA Q3 earnings preview, revenue estimate · Vera: Q2 2026 results (SEC 8-K, Exhibit 99.1) · Vera: Q2 2026 Form 10-Q · Investing.com: Raymond James on a Spherix survey of Trutakna and Voyxact (Oct 26, 2026) · AP: stocks fall on Nov 5, 2026
Accessed Nov 6, 2026: Yahoo Finance: VERA, S&P 500, Nasdaq Composite and XBI prices · CNBC: VERA quote and day range · BioPharma Dive: Vertex, ahead of FDA decision, calms fears surrounding kidney drug (Nov 2026) · BioPharma Dive: Vera wins FDA nod for Trutakna (Jul 7, 2026) · BioPharma Dive: Vertex kidney disease drug hits mark in late-stage study (Mar 9, 2026) · BioSpace: Vertex's IgA nephropathy drug derisked after Novartis, Vera approvals (BMO) · Otsuka: FDA accelerated approval for Voyxact (Nov 25, 2025) · Otsuka: two-year VISIONARY results for Voyxact (Aug 4, 2026) · Spherix Global Insights: Voyxact early uptake (Feb 24, 2026)
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.